Fused pentacyclic imidazole derivatives

A series of fused pentacyclic imidazole derivatives of formula (I), being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders;...

Full description

Saved in:
Bibliographic Details
Main Authors Quincey, Joanna Rachel, Deligny, Michael, Shaw, Michael Alan, Keyaerts, Jean, Jadot, Sophie, Mac Coss, Malcolm, Swinnen, Dominique Louis Léon, Zhu, Zhaoning, Brookings, Daniel Christopher, Hutchings, Martin Clive, Foricher, Yann, Filoche-Romme, Bruno, Calmiano, Mark Daniel, Schio, Laurent, Heer, Jag Paul, Selby, Matthew Duncan, Xuan, Mengyang, Evrard, Yves, De Haro Garcia, Teresa, Johnson, James Andrew
Format Patent
LanguageEnglish
Published 28.05.2021
Subjects
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:A series of fused pentacyclic imidazole derivatives of formula (I), being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders. In particular, the present invention is concerned with 6,7-dihydro-7,14-methanobenzimidazo[l,2-b][2,5]benzodiazocin-5(14H)-one derivatives and analogs thereof.
Bibliography:Application Number: NZ20150730256